Dianthus Therapeutics, Inc. (87E.F)
| Previous Close | 21.00 |
| Open | 22.40 |
| Bid | 23.60 x N/A |
| Ask | 23.80 x N/A |
| Day's Range | 22.40 - 22.40 |
| 52 Week Range | 10.50 - 29.60 |
| Volume | |
| Avg. Volume | 5 |
| Market Cap | 705.705M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted equity awards on May 1, 2024, to two newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to accep
- GlobeNewswire
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced an oral presentation for DNTH103 at the American Academy of Neurology (AAN) Annual Meeting, taking place April 13-18, 2024 in Denver, Colorado and virtually. DNTH103 is an investigational classical pathway inhibitor that
Simply Wall St.Dianthus Therapeutics Insiders Added US$2.05m Of Stock To Their Holdings
Multiple insiders secured a larger position in Dianthus Therapeutics, Inc. ( NASDAQ:DNTH ) shares over the last 12...
